{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T03:34:59Z","timestamp":1785814499699,"version":"3.56.0"},"reference-count":29,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T00:00:00Z","timestamp":1775433600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["HSS Journal\u00ae: The Musculoskeletal Journal of Hospital for Special Surgery"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>As the demand for total shoulder arthroplasty (TSA) increases, it is imperative to optimize preoperative risk factors. While glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are used for glycemic control or weight management in patients with obesity or diabetes, the impact of preoperative use on postoperative TSA outcomes in non-obese patients is unknown.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>We sought to answer the question: Does preoperative use of GLP-1 RAs lead to increased risk of medical or surgical complications after TSA?<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      We conducted a retrospective cohort study using data from the TriNetX Network to analyze non-obese patients (BMI &lt;30\u2009kg\/m\n                      <jats:sup>2<\/jats:sup>\n                      ) who underwent anatomic or reverse shoulder arthroplasty between 2013 (the inception of the network) and January 2024 and had at least 1\u2009year of follow up. Patients were categorized by preoperative GLP-1 RA use and matched 1:1 using propensity scores to balance the cohorts based on demographic variables and comorbidities. Outcomes assessed at 90\u2009days and 1\u2009year included revision surgery, emergency department visits, readmission, venous thromboembolism, pulmonary embolism, acute kidney injury, prosthetic joint stiffness, postoperative rotator cuff tear, dislocation, periprosthetic fracture or joint infection, surgical site infection, aspiration, cardiac arrest, and blood transfusion.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Among 108\u2009352 non-obese patients, 845 used GLP-1 RAs preoperatively. After propensity score matching, 845 patients remained in each cohort with no significant baseline differences. In the 90\u2009day postoperative period, there were no significant differences in any medical complications between the GLP-1 RA and control groups. Similarly, at 1\u2009year, there were no significant differences in any medical or surgical complications between groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>This retrospective cohort study found that preoperative GLP-1 RA use in non-obese TSA patients was not associated with an increased rate of major postoperative medical or surgical complications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Level of Evidence:<\/jats:title>\n                    <jats:p>Level III: retrospective cohort study.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/15563316261439127","type":"journal-article","created":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T06:45:19Z","timestamp":1775544319000},"page":"362-369","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Preoperative GLP-1 Receptor Agonist Use Is Not Associated With Complications in Non-Obese Patients Undergoing Total Shoulder Arthroplasty: A Propensity Score Matched Large Database Analysis"],"prefix":"10.1177","volume":"22","author":[{"given":"Alexander E.","family":"White","sequence":"first","affiliation":[{"name":"Department of Sports Medicine and Shoulder Surgery, Hospital for Special Surgery, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3378-6770","authenticated-orcid":false,"given":"Tyler","family":"Khilnani","sequence":"additional","affiliation":[{"name":"Department of Sports Medicine and Shoulder Surgery, Hospital for Special Surgery, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Argen","family":"Omurzakov","sequence":"additional","affiliation":[{"name":"Case Western Reserve University School of Medicine, Cleveland, OH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arsen M.","family":"Omurzakov","sequence":"additional","affiliation":[{"name":"Weill Cornell Medical College, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel A.","family":"Taylor","sequence":"additional","affiliation":[{"name":"Department of Sports Medicine and Shoulder Surgery, Hospital for Special Surgery, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,4,6]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"crossref","unstructured":"Rupani N Combescure C Silman A L\u00fcbbeke A Rees J. International trends in shoulder replacement: a meta-analysis from 11 public joint registers. Acta Orthop. 2024;95:348-357. https:\/\/doi.org\/10.2340\/17453674.2024.40948","DOI":"10.2340\/17453674.2024.40948"},{"key":"e_1_3_2_3_2","doi-asserted-by":"crossref","unstructured":"Wagner ER Farley KX Higgins I Wilson JM Daly CA Gottschalk MB. The incidence of shoulder arthroplasty: rise and future projections compared with hip and knee arthroplasty. J Shoulder Elbow Surg. 2020;29(12):2601-2609. https:\/\/doi.org\/10.1016\/j.jse.2020.03.049","DOI":"10.1016\/j.jse.2020.03.049"},{"key":"e_1_3_2_4_2","doi-asserted-by":"crossref","unstructured":"Davies M Pieber TR Hartoft-Nielsen ML Hansen OKH Jabbour S Rosenstock J. Effect of oral semaglutide compared with placebo and subcutaneous semaglutide on glycemic control in patients with type 2 diabetes: a randomized clinical trial. JAMA. 2017;318(15):1460. https:\/\/doi.org\/10.1001\/jama.2017.14752","DOI":"10.1001\/jama.2017.14752"},{"key":"e_1_3_2_5_2","doi-asserted-by":"crossref","unstructured":"Wadden TA Bailey TS Billings LK et al. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial. JAMA. 2021;325(14):1403. https:\/\/doi.org\/10.1001\/jama.2021.1831","DOI":"10.1001\/jama.2021.1831"},{"key":"e_1_3_2_6_2","doi-asserted-by":"crossref","unstructured":"Han SH Safeek R Ockerman K et al. Public interest in the off-label use of glucagon-like peptide 1 agonists (Ozempic) for cosmetic weight loss: a Google trends analysis. Aesthet Surg J. 2023;44(1):60-67. https:\/\/doi.org\/10.1093\/asj\/sjad211","DOI":"10.1093\/asj\/sjad211"},{"key":"e_1_3_2_7_2","doi-asserted-by":"crossref","unstructured":"Magruder ML Miskiewicz MJ Rodriguez AN Mont MA. Semaglutide use prior to total hip arthroplasty results in fewer postoperative prosthetic joint infections and readmissions. J Arthroplasty. 2024;39(3):716-720. https:\/\/doi.org\/10.1016\/j.arth.2023.12.023","DOI":"10.1016\/j.arth.2023.12.023"},{"key":"e_1_3_2_8_2","doi-asserted-by":"crossref","unstructured":"Magruder ML Yao VJH Rodriguez AN Ng MK Sasson V Erez O. Does semaglutide use decrease complications and costs following total knee arthroplasty?. J Arthroplasty. 2023;38(11):2311-2315.e1. https:\/\/doi.org\/10.1016\/j.arth.2023.05.071","DOI":"10.1016\/j.arth.2023.05.071"},{"key":"e_1_3_2_9_2","doi-asserted-by":"crossref","unstructured":"Lawand JJ Tansey PJ Ghali A et al. Glucagon-like peptide-1 receptor agonist use is associated with increased risk of perioperative complication and readmission following shoulder arthroplasty. J Shoulder Elbow Surg. 2024;34(5):1152-1157. https:\/\/doi.org\/10.1016\/j.jse.2024.09.012","DOI":"10.1016\/j.jse.2024.09.012"},{"key":"e_1_3_2_10_2","doi-asserted-by":"crossref","unstructured":"Elsabbagh Z Haft M Murali S Best M McFarland EG Srikumaran U. Does use of glucagon-like peptide-1 agonists increase perioperative complications in patients undergoing shoulder arthroplasty?. J Shoulder Elbow Surg. 2025;34(4):997-1006. https:\/\/doi.org\/10.1016\/j.jse.2024.07.045","DOI":"10.1016\/j.jse.2024.07.045"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.sart.2025.05.006"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.sart.2025.06.001"},{"key":"e_1_3_2_13_2","doi-asserted-by":"crossref","unstructured":"Watanabe JH Kwon J Nan B Reikes A. Trends in glucagon-like peptide 1 receptor agonist use 2014 to 2022. J Am Pharm Assoc (2003). 2024;64(1):133-138. https:\/\/doi.org\/10.1016\/j.japh.2023.10.002","DOI":"10.1016\/j.japh.2023.10.002"},{"key":"e_1_3_2_14_2","doi-asserted-by":"crossref","unstructured":"Cameron-Vendrig A Reheman A Siraj MA et al. Glucagon-like peptide 1 receptor activation attenuates platelet aggregation and thrombosis. Diabetes. 2016;65(6):1714-1723. https:\/\/doi.org\/10.2337\/db15-1141","DOI":"10.2337\/db15-1141"},{"key":"e_1_3_2_15_2","doi-asserted-by":"crossref","unstructured":"Husain M Birkenfeld AL Donsmark M et al. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2019;381(9):841-851. https:\/\/doi.org\/10.1056\/NEJMoa1901118","DOI":"10.1056\/NEJMoa1901118"},{"key":"e_1_3_2_16_2","doi-asserted-by":"crossref","unstructured":"Marso SP Bain SC Consoli A et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834-1844. https:\/\/doi.org\/10.1056\/NEJMoa1607141","DOI":"10.1056\/NEJMoa1607141"},{"key":"e_1_3_2_17_2","doi-asserted-by":"crossref","unstructured":"Verma S Poulter NR Bhatt DL et al. Effects of liraglutide on cardiovascular outcomes in patients with type 2 diabetes mellitus with or without history of myocardial infarction or stroke. Circulation. 2018;138(25):2884-2894. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.034516","DOI":"10.1161\/CIRCULATIONAHA.118.034516"},{"key":"e_1_3_2_18_2","doi-asserted-by":"crossref","unstructured":"Neeland IJ Linge J Birkenfeld AL. Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies. Diabetes Obes Metab. 2024;26(suppl 4):16-27. https:\/\/doi.org\/10.1111\/dom.15728","DOI":"10.1111\/dom.15728"},{"key":"e_1_3_2_19_2","doi-asserted-by":"crossref","unstructured":"Damluji AA Alfaraidhy M AlHajri N et al. Sarcopenia and cardiovascular diseases. Circulation. 2023;147(20):1534-1553. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.123.064071","DOI":"10.1161\/CIRCULATIONAHA.123.064071"},{"key":"e_1_3_2_20_2","doi-asserted-by":"crossref","unstructured":"Fu MC D\u2019Ambrosia C McLawhorn AS Schairer WW Padgett DE Cross MB. Malnutrition increases with obesity and is a stronger independent risk factor for postoperative complications: a propensity-adjusted analysis of total hip arthroplasty patients. J Arthroplasty. 2016;31(11):2415-2421. https:\/\/doi.org\/10.1016\/j.arth.2016.04.032","DOI":"10.1016\/j.arth.2016.04.032"},{"key":"e_1_3_2_21_2","doi-asserted-by":"crossref","unstructured":"Verhey JT Austin RP Tarabichi S et al. GLP-1 agonists for weight loss: do they increase complications in non-diabetic patients undergoing primary total hip arthroplasty?. J Arthroplasty. 2025;40(8S1):S101-S107. https:\/\/doi.org\/10.1016\/j.arth.2025.03.012","DOI":"10.1016\/j.arth.2025.03.012"},{"key":"e_1_3_2_22_2","doi-asserted-by":"crossref","unstructured":"Buddhiraju A Kagabo W Khanuja HS Oni JK Nikkel LE Hegde V. Decreased risk of readmission and complications with preoperative GLP-1 analog use in patients undergoing primary total joint arthroplasty. J Arthroplasty. 2024;39(12):2911-2915.e1. https:\/\/doi.org\/10.1016\/j.arth.2024.05.079","DOI":"10.1016\/j.arth.2024.05.079"},{"key":"e_1_3_2_23_2","doi-asserted-by":"crossref","unstructured":"Kim BI Khilnani TK LaValva SM Goodman SM Della Valle AG Lee GC. Utilization of glucagon-like peptide-1 receptor agonist at the time of total hip arthroplasty for patients who have morbid obesity. J Arthroplasty. 2024;40(9S1):S259-S264.e1. https:\/\/doi.org\/10.1016\/j.arth.2024.12.008","DOI":"10.1016\/j.arth.2024.12.008"},{"key":"e_1_3_2_24_2","doi-asserted-by":"crossref","unstructured":"Electricwala AJ Narkbunnam R Huddleston JI Maloney WJ Goodman SB Amanatullah DF. Obesity is associated with early total hip revision for aseptic loosening. J Arthroplasty. 2016;31(9 suppl):217-220. https:\/\/doi.org\/10.1016\/j.arth.2016.02.073","DOI":"10.1016\/j.arth.2016.02.073"},{"key":"e_1_3_2_25_2","doi-asserted-by":"crossref","unstructured":"Goodnough LH Finlay AK Huddleston JI Goodman SB Maloney WJ Amanatullah DF. Obesity is independently associated with early aseptic loosening in primary total hip arthroplasty. J Arthroplasty. 2018;33(3):882-886. https:\/\/doi.org\/10.1016\/j.arth.2017.09.069","DOI":"10.1016\/j.arth.2017.09.069"},{"key":"e_1_3_2_26_2","doi-asserted-by":"crossref","unstructured":"Jeschke E Citak M G\u00fcnster C et al. Obesity increases the risk of postoperative complications and revision rates following primary total hip arthroplasty: an analysis of 131 576 total hip arthroplasty cases. J Arthroplasty. 2018;33(7):2287-2292.e1. https:\/\/doi.org\/10.1016\/j.arth.2018.02.036","DOI":"10.1016\/j.arth.2018.02.036"},{"key":"e_1_3_2_27_2","doi-asserted-by":"crossref","unstructured":"Gaspari T Liu H Welungoda I et al. A GLP-1 receptor agonist liraglutide inhibits endothelial cell dysfunction and vascular adhesion molecule expression in an ApoE\u2212\/\u2212 mouse model. Diab Vasc Dis Res. 2011;8(2):117-124. https:\/\/doi.org\/10.1177\/1479164111404257","DOI":"10.1177\/1479164111404257"},{"key":"e_1_3_2_28_2","doi-asserted-by":"crossref","unstructured":"Adams JD Marshall WA. The use of tranexamic acid in hip and pelvic fracture surgeries. J Am Acad Orthop Surg. 2021;29(12):e576-e583. https:\/\/doi.org\/10.5435\/JAAOS-D-20-00750","DOI":"10.5435\/JAAOS-D-20-00750"},{"key":"e_1_3_2_29_2","doi-asserted-by":"crossref","unstructured":"Huang F Wu D Ma G Yin Z Wang Q. The use of tranexamic acid to reduce blood loss and transfusion in major orthopedic surgery: a meta-analysis. J Surg Res. 2014;186(1):318-327. https:\/\/doi.org\/10.1016\/j.jss.2013.08.020","DOI":"10.1016\/j.jss.2013.08.020"},{"key":"e_1_3_2_30_2","doi-asserted-by":"crossref","unstructured":"Mayfield CK Liu KC Richardson MK et al. Tranexamic acid use in total shoulder arthroplasty continues to increase and is safe in high-risk patients. J Shoulder Elbow Surg. 2025;34(5):1138-1151. https:\/\/doi.org\/10.1016\/j.jse.2024.08.051","DOI":"10.1016\/j.jse.2024.08.051"}],"container-title":["HSS Journal\u00ae: The Musculoskeletal Journal of Hospital for Special Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/15563316261439127","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/15563316261439127","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/15563316261439127","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T07:18:33Z","timestamp":1783495113000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/15563316261439127"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,6]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["10.1177\/15563316261439127"],"URL":"https:\/\/doi.org\/10.1177\/15563316261439127","relation":{},"ISSN":["1556-3316","1556-3324"],"issn-type":[{"value":"1556-3316","type":"print"},{"value":"1556-3324","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,6]]}}}